SEC Form 4 · accession 0001214659-18-001631
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles M Baum
Officer — President & CEO · Director
Period of report
Feb 23, 2018
Accepted (ET)
Feb 27, 2018 · 6:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 23, 2018 | M | 51,810 | $8.50 | A | 100,366 | D | |
| Common StockF2 | Feb 23, 2018 | S | 40,748 | $27.8922 | D | 59,618 | D | |
| Common StockF3,F5 | Feb 23, 2018 | S | 11,062 | $28.5578 | D | 50,932 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF4 | $8.50 | Feb 23, 2018 | M | 51,810 | D | — | Jul 16, 2020 | Common Stock | 51,810 | 155,430 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $27.45 to $28.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $28.45 to $28.725. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F420% of the shares subject to the stock option vested and became exercisable on the Date of Grant and 20% of the shares vested on each of the 1st 2nd, 3rd and 4th anniversaries of November 12, 2012. The options expire on July 16, 2020.
- F5Includes 2,376 shares acquired under the ESPP Purchase on 11/30/17.